Development of a Monomeric Inhibitory RNA Aptamer Specific for FGFR3 that Acts as an Activator When Dimerized

There have been limited options for people who suffer from fibroblast growth factor receptor (FGFR) signaling disorders. In this study, we developed RNA aptamers specific for FGFR3 as potential therapeutic agents. Using a structured aptamer library, we performed ten rounds of SELEX (systematic evolu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamatkar, Nachiket, Levy, Matthew, Hébert, Jean M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661505/
https://www.ncbi.nlm.nih.gov/pubmed/31357131
http://dx.doi.org/10.1016/j.omtn.2019.06.020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661505/
https://www.ncbi.nlm.nih.gov/pubmed/31357131
http://dx.doi.org/10.1016/j.omtn.2019.06.020

Ejemplares similares